Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?

समान संसाधन

• Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
  द्वारा: Gettinger, Scott, और अन्य
  प्रकाशित: (2016)
• Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
  द्वारा: Rizvi, Naiyer A., और अन्य
  प्रकाशित: (2016)
• First-line immunotherapy in advanced non-small-cell lung cancer
  द्वारा: Vanita Noronha, और अन्य
  प्रकाशित: (2019-01-01)
• Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
  द्वारा: Huabin Hu, और अन्य
  प्रकाशित: (2020-09-01)
• Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
  द्वारा: Hu, Huabin, और अन्य
  प्रकाशित: (2020)